Insider Selling: KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) CEO Sells 14,400 Shares of Stock

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) CEO Benjamin L. Palleiko sold 14,400 shares of the business’s stock in a transaction on Monday, November 18th. The stock was sold at an average price of $9.26, for a total value of $133,344.00. Following the transaction, the chief executive officer now owns 266,598 shares of the company’s stock, valued at $2,468,697.48. This trade represents a 5.12 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.

KalVista Pharmaceuticals Stock Up 3.5 %

Shares of KalVista Pharmaceuticals stock opened at $9.28 on Friday. KalVista Pharmaceuticals, Inc. has a 12-month low of $7.39 and a 12-month high of $16.88. The firm has a market capitalization of $400.82 million, a PE ratio of -2.63 and a beta of 0.92. The stock’s fifty day moving average is $11.04 and its 200-day moving average is $11.99.

KalVista Pharmaceuticals (NASDAQ:KALV) last posted its quarterly earnings data on Thursday, September 5th. The specialty pharmaceutical company reported ($0.87) EPS for the quarter, beating analysts’ consensus estimates of ($0.91) by $0.04. Analysts expect that KalVista Pharmaceuticals, Inc. will post -2.7 EPS for the current year.

Institutional Trading of KalVista Pharmaceuticals

Hedge funds have recently modified their holdings of the business. BNP Paribas Financial Markets lifted its stake in KalVista Pharmaceuticals by 94.5% in the 1st quarter. BNP Paribas Financial Markets now owns 18,013 shares of the specialty pharmaceutical company’s stock worth $214,000 after acquiring an additional 8,750 shares in the last quarter. EntryPoint Capital LLC purchased a new stake in KalVista Pharmaceuticals in the 1st quarter worth approximately $92,000. Capital World Investors purchased a new stake in KalVista Pharmaceuticals in the 1st quarter worth approximately $17,370,000. PEAK6 Investments LLC acquired a new stake in shares of KalVista Pharmaceuticals during the 1st quarter valued at $178,000. Finally, Price T Rowe Associates Inc. MD increased its stake in shares of KalVista Pharmaceuticals by 4.5% in the first quarter. Price T Rowe Associates Inc. MD now owns 22,142 shares of the specialty pharmaceutical company’s stock worth $263,000 after acquiring an additional 944 shares during the last quarter.

Wall Street Analyst Weigh In

A number of research firms recently commented on KALV. Needham & Company LLC reiterated a “buy” rating and set a $32.00 price objective on shares of KalVista Pharmaceuticals in a research note on Friday, September 6th. HC Wainwright reissued a “buy” rating and issued a $20.00 price target on shares of KalVista Pharmaceuticals in a report on Monday, October 7th. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of KalVista Pharmaceuticals in a report on Monday, September 9th.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).